|Other Names||Vascular endothelial growth factor B, VEGF-B, VEGF-related factor, VRF, VEGFB, VRF|
|Target/Specificity||The synthetic peptide sequence is selected from aa 22-37 of HUMAN VEGFB|
|Format||Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Growth factor for endothelial cells. VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.|
|Cellular Location||Secreted. Note=Secreted but remains associated to cells or to the extracellular matrix unless released by heparin|
|Tissue Location||Expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Vascular endothelial growth factors (VEGFs) are a family of closely related growth factors having a conserved pattern of eight cysteine residues and sharing common VEGF receptors. VEGFs stimulate endothelial cells, induce angiogenesis, promote cell migration, increase vascular permeability, and inhibit apoptosis. VEGFB has structural similarities to VEGF and PIGF and is frequently co-expressed with VEGF. There are two alternatively spliced isoforms of VEGFB: VEGFB 167 and VEGFB 186. VEGFB 167, a highly basic heparin-binding protein, remains with the cell or extracellular matrix whereas, VEGFB 186 is readily secreted. VEGFB stimulates endothelial cell proliferation. VEGFB binds to the tyrosine kinase receptor VEGFR1 (flt1) and does not bind to VEGFR2. Vascular Endothelial Growth Factor B is widely expressed but is most abundant in heart, skeletal muscle, and pancreas. It has been suggested that VEGFB expression in human primary breast cancers is associated with lymph node metastasis. The genes that encode VEGFB have been mapped to chromosome 11q13.
Trompezinski, S., et al., Exp. Dermatol. 13(2):98-105 (2004).
Qi, J.H., et al., Nat. Med. 9(4):407-415 (2003).
Joukov, V., et al., J. Cell. Physiol. 173(2):211-215 (1997).
Olofsson, B., et al., J. Biol. Chem. 271(32):19310-19317 (1996).
Olofsson, B., et al., Proc. Natl. Acad. Sci. U.S.A. 93(6):2576-2581 (1996).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.